{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T09:55:36Z","timestamp":1781344536289,"version":"3.54.1"},"reference-count":24,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cytomegalovirus (CMV) is one of the most common and clinically significant viral infections following allogeneic hematopoietic cell transplantation (HCT). Currently available options for CMV prophylaxis and treatment present challenges related to side effects and cost.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective medical record review, the incidence of clinically significant CMV infection (CMV disease or reactivation requiring preemptive treatment) following allogeneic HCT was compared in patients receiving valacyclovir 1\u2005g three times daily versus acyclovir 400\u2005mg every 12\u2005h for viral prophylaxis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-five patients who received valacyclovir were matched based on propensity scoring to 35 patients who received acyclovir. All patients received reduced-intensity conditioning regimens containing anti-thymocyte globulin. Clinically significant CMV infection by day\u2009+\u2009180 was lower in the valacyclovir group compared to the acyclovir group (18% vs. 57%, p\u2009=\u20090.0004). Patients receiving valacyclovir prophylaxis also had less severe infection evidenced by a reduction in CMV disease, lower peak CMV titers, delayed CMV reactivation, and less secondary neutropenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Prospective evaluation of valacyclovir 1\u2005g three times daily for viral prophylaxis following allogeneic HCT is warranted. Due to valacyclovir's favorable toxicity profile and affordable cost, it has the potential to benefit patients on a broad scale as an option for CMV prophylaxis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552211060479","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T12:43:49Z","timestamp":1638449029000},"page":"130-137","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["High dose valacyclovir for cytomegalovirus prophylaxis following allogeneic hematopoietic cell transplantation"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4876-9690","authenticated-orcid":false,"given":"Kelly G","family":"Hawks","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services, Virginia Commonwealth University Health System, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Fegley","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Virginia Commonwealth University Health System, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy T","family":"Sabo","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Virginia Commonwealth University, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine H","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Massey Cancer Center, Virginia Commonwealth University Health System, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir A","family":"Toor","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Massey Cancer Center, Virginia Commonwealth University Health System, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"key":"bibr1-10781552211060479","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.08.010"},{"key":"bibr2-10781552211060479","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.12.705"},{"key":"bibr3-10781552211060479","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01092-x"},{"key":"bibr4-10781552211060479","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13096"},{"key":"bibr5-10781552211060479","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2010.11.011"},{"key":"bibr6-10781552211060479","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00289-6"},{"key":"bibr7-10781552211060479","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.03.020"},{"key":"bibr8-10781552211060479","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000956"},{"key":"bibr9-10781552211060479","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.06.019"},{"key":"bibr10-10781552211060479","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","volume":"19","author":"Ljungman P","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"bibr11-10781552211060479","unstructured":"Letermovir [package insert]. Whitehouse Station, NJ: Merck; 2017. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/p\/prevymis\/prevymis_pi.pdf."},{"key":"bibr12-10781552211060479","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.8.3050"},{"key":"bibr13-10781552211060479","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(03)70007-X"},{"key":"bibr14-10781552211060479","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.03.011"},{"key":"bibr15-10781552211060479","doi-asserted-by":"publisher","DOI":"10.1086\/339329"},{"key":"bibr16-10781552211060479","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.11.005"},{"key":"bibr17-10781552211060479","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706640"},{"key":"bibr18-10781552211060479","unstructured":"Average wholesale pricing information obtained from Medi-Span, accessed July 2020."},{"key":"bibr19-10781552211060479","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705699"},{"key":"bibr20-10781552211060479","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0993"},{"key":"bibr21-10781552211060479","unstructured":"Clinicaltrials.gov. NCT03930615. Extension of letermovir (LET) from day 100 to day 200 post-transplant for the prevention of cytomegalovirus (CMV) infection in hematopoietic stem cell transplant (HSCT) participants (MK-8228-040). (accessed 2 January 2021)."},{"key":"bibr22-10781552211060479","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.07.002"},{"key":"bibr23-10781552211060479","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.09.018"},{"key":"bibr24-10781552211060479","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.05.008"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211060479","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552211060479","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211060479","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:25:44Z","timestamp":1777688744000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552211060479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1177\/10781552211060479"],"URL":"https:\/\/doi.org\/10.1177\/10781552211060479","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,2]]}}}